Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintains a $7 price target.
July 23, 2024 | 9:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies and maintained a $7 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst suggests positive sentiment and confidence in Taysha Gene Therapies' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100